JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2021, 70(4):136-141 | DOI: 10.5817/CSF2021-4-136

68Ga-DOTATOC

Michal Budinský1,*, Petr Vyšinský1, Stanislav Synek1, Beatrix Bencsiková2, Iveta Selingerová3, Zdeněk Řehák4
1 Masarykův onkologický ústav, Ústavní lékárna, Brno
2 Masarykův onkologický ústav, Klinika komplexní onkologické péče, Brno
3 Masarykův onkologický ústav, Oddělení laboratorní medicíny, Brno
4 Masarykův onkologický ústav, Oddělení nukleární medicíny, Brno

The radiopharmaceutical 68Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult 68Ga-radiopharmacy and may increase and improve the care of oncology patients.

Keywords: 68Ga-DOTATOC; radiopharmacy; neuroendocrine tumors

Received: April 30, 2021; Accepted: June 29, 2021; Published: April 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Budinský M, Vyšinský P, Synek S, Bencsiková B, Selingerová I, Řehák Z. 68Ga-DOTATOC. Čes. slov. farm. 2021;70(4):136-141. doi: 10.5817/CSF2021-4-136.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Patel Y. C. Somatostatin and its receptor family. Frontiers in Neuroendocrinology 1999; 20(3), 157-198. Go to original source... Go to PubMed...
    2. Patel Y. C., Strikant C. B. Somatostatin receptors. Trends Endocrinol Metab. 1997; 8(10), 398-405. Go to original source... Go to PubMed...
    3. Papotti M., Bongiovanni M., Volante M., Allia E., Landolfi S., Helboe L., Schindler M., Cole S. L., Bussolati G. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse- transcriptase polymerase chain reaction analysis. Virchows arch. 2002; 440(5), 461-175. Go to original source... Go to PubMed...
    4. Vítek P. Neuroendokrinní nádory, in Onkologie v klinické praxi. Standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů. Praha: Mladá fronta 2019.
    5. Sedláčková E., Bajčiová V., a kol. Epidemiologie NEN ve světe a v ČR, registry. In: Neuroendokrinní nádory. Praha: Maxdorf 2016.
    6. Wang L., Tang K., Zhang Q., Li H., Wen Z., Zhang H. Somatostatin Receptor-Based MoleculaImaging and Therapy for Neuroendocrine Tumors. Biomed Res Int. 2013; 2013, 102819. Go to original source... Go to PubMed...
    7. Pauwels E., Cleeren F., Bormans G., Deroose C. M. Somatostatin receptor PET ligands - the next generation for clinical practice. Am. J. Nucl. Med. Mol. Imag. 2018; 8(5), 311-331.
    8. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., Kovacs P., Guggenberg E., Bale R., Virgolini I. J. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007; 48, 508-518. Go to original source... Go to PubMed...
    9. Bencsiková B., Řehák Z., Budinský M., Hejnová R., Kozáková Š., Kiss I., Demlova R., Svoboda M. 68Ga- DOTA-TOC PET/CT vyšetření u pacienta s gastroenteropankreatickým neuroendokrinním nádorem - první vyšetření v České republice. Klin. Onkol. 2019; 32(5), 390-392.
    10. Monaharan P., Lamarca A., Navalkissoor S., Calero J., Chan P. S, Julyan P., Sierra M., Caplin M., Valle J. Safety, tolerability and clinical implementation of "ready-to-use" 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastropancreatic neuroendocrine tumors (GEP-NETs). ESMO Open. 2020; 5, e000650. Go to original source... Go to PubMed...
    11. Calero J. Kits or synthesis modules? A review of both strategies. Ga-68 for beginners. London: UKRG 2018.
    12. Murby B. Radiation risk assessment. Ga-68 for beginners. London: UKRG 2018.

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.